270 related articles for article (PubMed ID: 34661827)
1. A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes.
Chouaid C; Filleron T; Debieuvre D; Pérol M; Girard N; Dansin E; Lena H; Gervais R; Cousin S; Otto J; Schott R; Planchard D; Madroszyk A; Kaderbhai C; Dubray-Longeras P; Hiret S; Pichon E; Clément-Duchêne C; Chenuc G; Simon G; Bosquet L; QUantin X
Target Oncol; 2021 Nov; 16(6):801-811. PubMed ID: 34661827
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
Burnett H; Emich H; Carroll C; Stapleton N; Mahadevia P; Li T
PLoS One; 2021; 16(3):e0247620. PubMed ID: 33684140
[TBL] [Abstract][Full Text] [Related]
3. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
[TBL] [Abstract][Full Text] [Related]
4. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer
Kim TM; Girard N; Low GKM; Zhuo J; Yu DY; Yang Y; Murota M; Lim CTK; Kleinman NJ; Cho BC
Acta Oncol; 2023 Dec; 62(12):1689-1697. PubMed ID: 37938161
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
Leduc C; Merlio JP; Besse B; Blons H; Debieuvre D; Bringuier PP; Monnet I; Rouquette I; Fraboulet-Moreau S; Lemoine A; Pouessel D; Mosser J; Vaylet F; Langlais A; Missy P; Morin F; Moro-Sibilot D; Cadranel J; Barlesi F; Beau-Faller M;
Ann Oncol; 2017 Nov; 28(11):2715-2724. PubMed ID: 28945865
[TBL] [Abstract][Full Text] [Related]
6. Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by
Vadagam P; Waters D; Lee I; Chen J; Tian D; Near AM; Lyle D; Vanderpoel J
J Med Econ; 2024; 27(1):219-229. PubMed ID: 38269536
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
8. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea.
Byeon S; Kim Y; Lim SW; Cho JH; Park S; Lee J; Sun JM; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2019 Apr; 51(2):623-631. PubMed ID: 30049203
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
12. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
Sari M; Aydiner A
J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
[TBL] [Abstract][Full Text] [Related]
13. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
14. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
16. [First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient
with EGFR Exon 20 Insertion Mutantion].
Li Z; Wei T; Zeng D; Zhao L; Zhang J; Chen L
Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):241-244. PubMed ID: 38590198
[TBL] [Abstract][Full Text] [Related]
17. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.
Garg A; Batra U; Choudhary P; Jain D; Khurana S; Malik PS; Muthu V; Prasad KT; Singh N; Suri T; Mohan A
Curr Probl Cancer; 2020 Jun; 44(3):100570. PubMed ID: 32498966
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them].
Shi Y; Li P; Li B; Zhang F; Huang S; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):299-305. PubMed ID: 31109439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
